Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.14
HOLX's Cash to Debt is ranked lower than
51% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. HOLX: 0.14 )
HOLX' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.14

Equity to Asset 0.26
HOLX's Equity to Asset is ranked higher than
51% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.57 vs. HOLX: 0.26 )
HOLX' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.88
Current: 0.26

0.22
0.88
Interest Coverage 1.27
HOLX's Interest Coverage is ranked lower than
57% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.94 vs. HOLX: 1.27 )
HOLX' s 10-Year Interest Coverage Range
Min: 0.55   Max: 9999.99
Current: 1.27

0.55
9999.99
F-Score: 7
Z-Score: 0.86
M-Score: -2.73
WACC vs ROIC
9.30%
4.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.52
HOLX's Operating margin (%) is ranked higher than
83% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.43 vs. HOLX: 12.52 )
HOLX' s 10-Year Operating margin (%) Range
Min: -123.18   Max: 20.99
Current: 12.52

-123.18
20.99
Net-margin (%) 2.02
HOLX's Net-margin (%) is ranked higher than
68% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.28 vs. HOLX: 2.02 )
HOLX' s 10-Year Net-margin (%) Range
Min: -135.4   Max: 16.59
Current: 2.02

-135.4
16.59
ROE (%) 2.56
HOLX's ROE (%) is ranked higher than
67% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. HOLX: 2.56 )
HOLX' s 10-Year ROE (%) Range
Min: -60.17   Max: 17.54
Current: 2.56

-60.17
17.54
ROA (%) 0.62
HOLX's ROA (%) is ranked higher than
66% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.93 vs. HOLX: 0.62 )
HOLX' s 10-Year ROA (%) Range
Min: -32.08   Max: 14.52
Current: 0.62

-32.08
14.52
ROC (Joel Greenblatt) (%) 41.87
HOLX's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.59 vs. HOLX: 41.87 )
HOLX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -369.22   Max: 99.3
Current: 41.87

-369.22
99.3
Revenue Growth (3Y)(%) 10.30
HOLX's Revenue Growth (3Y)(%) is ranked higher than
87% of the 263 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. HOLX: 10.30 )
HOLX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7.7   Max: 35.9
Current: 10.3

-7.7
35.9
EBITDA Growth (3Y)(%) 5.00
HOLX's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. HOLX: 5.00 )
HOLX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -5.1   Max: 90.5
Current: 5

-5.1
90.5
EPS Growth (3Y)(%) -53.30
HOLX's EPS Growth (3Y)(%) is ranked higher than
50% of the 229 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. HOLX: -53.30 )
HOLX' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.1   Max: 369.3
Current: -53.3

-68.1
369.3
» HOLX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

HOLX Guru Trades in Q1 2014

Murray Stahl 36,555 sh (New)
Steven Cohen 191,791 sh (+837.39%)
Irving Kahn 1,556,979 sh (+15.37%)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Prem Watsa 20,000 sh (unchged)
Jean-Marie Eveillard 17,000 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc Sold Out
Jim Simons Sold Out
Ken Fisher 129,100 sh (-9.85%)
Joel Greenblatt 100,601 sh (-35.86%)
» More
Q2 2014

HOLX Guru Trades in Q2 2014

Jim Simons 949,418 sh (New)
Joel Greenblatt 205,907 sh (+104.68%)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Prem Watsa 20,000 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Ken Fisher 129,100 sh (unchged)
Jean-Marie Eveillard Sold Out
Irving Kahn 1,541,729 sh (-0.98%)
Murray Stahl 30,951 sh (-15.33%)
» More
Q3 2014

HOLX Guru Trades in Q3 2014

Paul Tudor Jones 660,469 sh (New)
Jim Simons 1,574,218 sh (+65.81%)
Murray Stahl 33,815 sh (+9.25%)
Ken Fisher 129,690 sh (+0.46%)
Prem Watsa 20,000 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Irving Kahn 1,541,159 sh (-0.04%)
Joel Greenblatt 16,119 sh (-92.17%)
» More
Q4 2014

HOLX Guru Trades in Q4 2014

Jim Simons 2,260,618 sh (+43.60%)
Prem Watsa 20,000 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 128,300 sh (-1.07%)
Murray Stahl 31,389 sh (-7.17%)
Irving Kahn 1,420,442 sh (-7.83%)
Paul Tudor Jones 29,530 sh (-95.53%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 192.60
HOLX's P/E(ttm) is ranked higher than
63% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 56.80 vs. HOLX: 192.60 )
HOLX' s 10-Year P/E(ttm) Range
Min: 25.24   Max: 470.18
Current: 192.6

25.24
470.18
Forward P/E 20.00
HOLX's Forward P/E is ranked higher than
87% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.73 vs. HOLX: 20.00 )
N/A
PE(NRI) 183.80
HOLX's PE(NRI) is ranked higher than
70% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 58.30 vs. HOLX: 183.80 )
HOLX' s 10-Year PE(NRI) Range
Min: 25.41   Max: 446.67
Current: 183.8

25.41
446.67
P/B 4.40
HOLX's P/B is ranked higher than
58% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. HOLX: 4.40 )
HOLX' s 10-Year P/B Range
Min: 0.59   Max: 10.61
Current: 4.4

0.59
10.61
P/S 3.71
HOLX's P/S is ranked higher than
52% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.32 vs. HOLX: 3.71 )
HOLX' s 10-Year P/S Range
Min: 1.47   Max: 7.73
Current: 3.71

1.47
7.73
PFCF 22.40
HOLX's PFCF is ranked higher than
90% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 97.29 vs. HOLX: 22.40 )
HOLX' s 10-Year PFCF Range
Min: 6.51   Max: 2932
Current: 22.4

6.51
2932
POCF 18.18
HOLX's POCF is ranked higher than
83% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.60 vs. HOLX: 18.18 )
HOLX' s 10-Year POCF Range
Min: 5.48   Max: 124.63
Current: 18.18

5.48
124.63
EV-to-EBIT 39.35
HOLX's EV-to-EBIT is ranked higher than
75% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 36.87 vs. HOLX: 39.35 )
HOLX' s 10-Year EV-to-EBIT Range
Min: -125.3   Max: 118
Current: 39.35

-125.3
118
Current Ratio 2.20
HOLX's Current Ratio is ranked higher than
66% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. HOLX: 2.20 )
HOLX' s 10-Year Current Ratio Range
Min: 1.07   Max: 7.31
Current: 2.2

1.07
7.31
Quick Ratio 1.69
HOLX's Quick Ratio is ranked higher than
71% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. HOLX: 1.69 )
HOLX' s 10-Year Quick Ratio Range
Min: 0.85   Max: 6.57
Current: 1.69

0.85
6.57
Days Inventory 89.43
HOLX's Days Inventory is ranked higher than
85% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 133.28 vs. HOLX: 89.43 )
HOLX' s 10-Year Days Inventory Range
Min: 65.34   Max: 159.78
Current: 89.43

65.34
159.78
Days Sales Outstanding 56.86
HOLX's Days Sales Outstanding is ranked higher than
81% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.74 vs. HOLX: 56.86 )
HOLX' s 10-Year Days Sales Outstanding Range
Min: 57.11   Max: 195.7
Current: 56.86

57.11
195.7

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.60
HOLX's Price/DCF (Projected) is ranked higher than
87% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. HOLX: 1.60 )
HOLX' s 10-Year Price/DCF (Projected) Range
Min: 0.41   Max: 12.14
Current: 1.6

0.41
12.14
Price/Median PS Value 1.30
HOLX's Price/Median PS Value is ranked higher than
73% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. HOLX: 1.30 )
HOLX' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 2.71
Current: 1.3

0.16
2.71
Earnings Yield (Greenblatt) 2.50
HOLX's Earnings Yield (Greenblatt) is ranked higher than
69% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. HOLX: 2.50 )
HOLX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 7.9
Current: 2.5

0.8
7.9
Forward Rate of Return (Yacktman) 19.97
HOLX's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. HOLX: 19.97 )
HOLX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.8   Max: 76.6
Current: 19.97

-0.8
76.6

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 2,600 2,693 2,802
EPS($) 1.57 1.70 1.94
EPS without NRI($) 1.57 1.70 1.94

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HO1.Germany,
Hologic Inc was incorporated in Massachusetts in October 1985 and reincorporated in Delaware in March 1990. The Company is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. The Company's core business segments are focused on breast health, diagnostics, GYN surgical and skeletal health. The Company's breast health products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), minimally invasive breast biopsy and tissue extraction devices, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products. It has also developed a new breast imaging platform, Dimensions, which utilizes a new technology, tomosynthesis, to produce 3D images. The Company's diagnostic product offerings include the ThinPrep System used mainly for cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test for pre-term birth risk assessment. The Company's surgical product offerings include the NovaSure System, and the Adiana System. The NovaSure System enables physicians to treat women suffering from excessive menstrual bleeding in a minimally invasive manner. The Adiana System is a form of permanent female contraception intended as an alternative to tubal ligation. It sells and services its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company's mammography and related products and subsystems compete with products offered by a number of competitors, including GE, Siemens, Philips, PlanMed, Agfa, Carestream Health, Fuji, IMS Giotto, Sectra and Toshiba. The manufacture, sale, lease and service of medical diagnostic and surgical devices and pharmaceutical products intended for commercial use are subject to extensive governmental regulation by the FDA in the United States and by a variety of regulatory agencies in other countries.
» More Articles for HOLX

Headlines

Articles On GuruFocus.com
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 
Carl Icahn Letter On His Standstill Agreement With Ebay Jan 22 2015 
actionview Dec 06 2014 
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
Paul Tudor Jones Lives Up to Reputation As Active Trader in Third Quarter Nov 24 2014 
No More a Simple Distributor Sep 07 2014 
Carl Icahn Bets on Hologic; Should You? Aug 19 2014 
Weekly CFO Sells Highlight: Travelers Companies, Facebook, Hologic May 12 2014 
Weekly CEO Buys Highlight: HOLX, EPB, CLMS, IDTI, BYI Feb 17 2014 
GuruFocus Guru of the Year Carl Icahn's Top Fourth Quarter Holdings Feb 14 2014 


More From Other Websites
Adi Capital’s Paritosh Gupta Beat the Market but Trailed His Wife in Q1 Apr 21 2015
Microsoft Corporation (MSFT), Valeant Pharmaceuticals Intl Inc (VRX): Partner Fund Management’s... Apr 18 2015
Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer... Apr 16 2015
Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer... Apr 16 2015
Cyberonics-Sorin $2.7B Deal Gets US Antitrust Go-Ahead - Analyst Blog Apr 15 2015
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2015 on Wednesday, April 29,... Apr 06 2015
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2015 on Wednesday, April 29,... Apr 06 2015
Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are... Apr 01 2015
IDEXX Banks on Strong CAG, Global Growth Continues - Analyst Blog Apr 01 2015
Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are... Apr 01 2015
Zacks Industry Outlook Highlights: Boston Scientific, Edwards Lifesciences, Natus Medical, Hologic... Mar 27 2015
Coverage initiated on Hologic by UBS Mar 10 2015
Hologic (HOLX) Continues to Impress: Should You Invest Now? - Analyst Blog Mar 06 2015
HOLOGIC INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 04 2015
Hologic (HOLX) Stock Gaining Today After Canaccord Price Target Increase Feb 19 2015
Relational reduces position in Hologic Feb 19 2015
Edwards Lifesciences (EW) Shines on Solid Q4, THV Sales - Analyst Blog Feb 19 2015
HOLOGIC INC Financials Feb 05 2015
Hologic to Present at Three Upcoming Investor Conferences Feb 04 2015
Hologic to Present at Three Upcoming Investor Conferences Feb 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK